BRIEF—Debiopharm announces Debio 1143 study update

13 August 2020

Debiopharm has announced the release of compelling follow-up results from the Phase II study of Debio 1143 alongside chemo-radiation therapy (CRT) versus CRT alone in high-risk patients with locally advanced squamous cell carcinoma of the head and neck.

There were promising overall survival (OS) outcomes at three years, according to the Swiss family-owned biopharma, with the Debio 1143 patients showing a statistically- and clinically-significant improvement in OS versus the control group.

The results also confirm the sustainability of the promising two-year outcomes recently published in Lancet1 by demonstrating continued, statistically-significant improvements across all other major endpoints including the doubling of the progression free survival rate along with superior duration of response.



Companies featured in this story

More ones to watch >